Tag Archives: oncology

BIO Investor Forum Company Snapshot: Opsona Therapeutics

opsona115x76

Opsona Therapeutics will be participating in the upcoming BIO Investor Forum, and will be giving a presentation on their work in the autoimmune/inflammatory diseases and oncology space (among other indications). To learn more about their company, please read one of our final company snapshots below. Company Snapshot What is your company’s lead product or technology? Opsona’s lead product OPN-305 is a fully humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which is in clinical development as Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Investor Forum Company Snapshot: DLVR Therapeutics

DLVR

DLVR Therapeutics will be presenting in the Discovery Company Track at the upcoming BIO Investor Forum. Below, this early-stage company based in Ontario, answers our snapshot questions to provide attendees and readers with more perspective on their work. Company Snapshot What is your company’s lead product or technology?  DLVR is developing an innovative nanoparticle for delivery of nucleotides, such as small interfering RNA (siRNA). Our key differentiator is the synthesis of an HDL-mimetic phospholipid-based particle Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

Medicare Part B: Barriers to Cancer Treatment

Davenport-Ennis

The National Patient Advocate Foundation (PAF) has seen a notable rise in calls for assistance from both Medicare beneficiaries and cancer doctors regarding difficulty accessing certain cancer drugs in the physician office setting, where most patients receive their care. As a result, patients are being forced to seek cancer treatment in the hospital setting to access their life-saving cancer medicines; this displacement disrupts their continuum of care, is inconvenient, and is more costly to the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Cancer Stem Cell Therapy: Real Or Just Hype?

Stem Cell Therapy

Also known as tumor-initiating cells, cancer stem cells (CSC) have unique capability endemic to stem cells of self-renewal and differentiation, thereby causing tumor relapse and/or metastatis. While traditional cancer treatments focus on tumor shrinkage, it’s a distinct possibility that these agents do not effectively destroy all of the CSCs, causing the tumor to reappear. The CSC theory is relatively new, so the treatment pipeline is still in its early stages. Nathan Sadeghi-Nejad, a contributor to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,